Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Free Report) have received an average rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $31.67.

ZNTL has been the subject of several research reports. Stifel Nicolaus lowered their price objective on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. HC Wainwright lowered their price objective on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Finally, Wedbush boosted their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th.

View Our Latest Analysis on ZNTL

Insider Activity

In other news, insider Diana Hausman sold 3,356 shares of the business’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the sale, the insider now owns 373,876 shares in the company, valued at approximately $4,718,315.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the completion of the transaction, the chief financial officer now owns 633,680 shares in the company, valued at approximately $7,591,486.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Diana Hausman sold 3,356 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the transaction, the insider now owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Opaleye Management Inc. bought a new position in shares of Zentalis Pharmaceuticals during the 1st quarter worth approximately $3,152,000. Kennedy Capital Management LLC acquired a new position in Zentalis Pharmaceuticals during the 1st quarter valued at approximately $189,000. Price T Rowe Associates Inc. MD increased its stake in Zentalis Pharmaceuticals by 20.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after purchasing an additional 585,644 shares in the last quarter. ProShare Advisors LLC increased its stake in Zentalis Pharmaceuticals by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after purchasing an additional 1,274 shares in the last quarter. Finally, 49 Wealth Management LLC acquired a new position in Zentalis Pharmaceuticals during the 1st quarter valued at approximately $172,000.

Zentalis Pharmaceuticals Trading Down 4.9 %

ZNTL stock opened at $11.08 on Friday. Zentalis Pharmaceuticals has a 12 month low of $9.56 and a 12 month high of $30.53. The company has a 50-day moving average price of $12.55 and a 200 day moving average price of $13.15. The stock has a market cap of $787.01 million, a PE ratio of -3.33 and a beta of 1.83.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.91. The firm had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $35.00 million. During the same period in the prior year, the firm posted ($1.07) earnings per share. Sell-side analysts forecast that Zentalis Pharmaceuticals will post -2.72 EPS for the current year.

About Zentalis Pharmaceuticals

(Get Free Report

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Read More

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.